Renaissance Capital logo

Maravai LifeSciences Priced, Nasdaq: MRVI

Provides genetic products and testing services for drug development and research.

Industry: Health Care

Latest Trade: $29.40 0.00 (0.0%)

First Day Return: +10.6%

Return from IPO: +8.9%

Industry: Health Care

We are a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. Our more than 5,000 customers as of September 30, 2020 include the top 20 global biopharmaceutical companies ranked by research and development expenditures according to industry consultants, and many other emerging biopharmaceutical and life sciences research companies, as well as leading academic research institutes and in vitro diagnostics companies. Our products address the key phases of biopharmaceutical development and include complex nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. Our businesses principally serve high growth market segments in biopharmaceutical development and manufacturing. We estimate that the market segments we serve are growing at a weighted average blended rate of 20% per annum. In particular, the field of cell and gene therapy has emerged as one of the fastest growing treatment modalities to address a host of human conditions.
more less
IPO News for Maravai LifeSciences
more
IPO Data
IPO File Date 10/29/2020
Offer Price $27.00
Price Range $24.00 - $27.00
Offer Shares (mm) 60.0
Deal Size ($mm) $1,620
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 11/19/2020
Offer Price $27.00
Price Range $24.00 - $27.00
Offer Shares (mm) 60.0
Deal Size ($mm) $1,620
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters San Diego, CA
Founded 2014
Employees 390
Website www.maravai.com